Welcome to our dedicated page for Cue Biopharma SEC filings (Ticker: CUE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cue Biopharma, Inc. filings document material events, governance actions, operating results, and capital-structure matters for a clinical-stage biopharmaceutical company focused on immune-modulating biologics. The company's 8-K reports cover executive transitions, collaboration milestones, financial results, registered common stock matters, and amendments related to a reverse stock split.
Proxy and meeting-related filings describe director elections, auditor ratification, executive compensation votes, stockholder proposal procedures, and amendments to governing documents. Other disclosures address research and development programs including CUE-401, CUE-501, the Immuno-STAT platform, collaboration and license agreements, equity compensation arrangements, and risk factors associated with clinical-stage biotechnology operations.
Driehaus Capital Management LLC reported beneficial ownership of 292,144 shares of Cue Biopharma, Inc. common stock on a Schedule 13G. This represents 6.96% of the outstanding common stock. All of these shares are reported with shared voting and shared dispositive power; Driehaus reports no sole voting or dispositive power.
The shares are held in fully discretionary accounts for investment advisory clients, including Driehaus Life Sciences Master Fund, L.P., which has rights with respect to more than 5% of Cue Biopharma’s common stock. Clients retain the economic rights to dividends and sale proceeds.
Cue Biopharma, Inc. filed a shelf registration to permit the resale by existing investors of up to 1,505,570 shares of common stock. The registered shares comprise 1,418,070 shares issued in a July 2026 private placement and 87,500 shares issuable upon exercise of outstanding Pre-Funded Warrants with a cash exercise price of $0.001 per share.
The investors originally purchased the securities for aggregate gross proceeds of approximately $50.0 million at $33.21 per share (or $33.209 per Pre-Funded Warrant). Cue Biopharma will not receive proceeds from any resale of these shares, other than nominal cash received upon warrant exercises. As of July 24, 2026, 6,826,387 shares of common stock were outstanding. The company’s independent auditor’s report for 2024–2025 includes an explanatory paragraph regarding the company’s ability to continue as a going concern.
Cue Biopharma, Inc. appointed James Ahlers as Chief Financial Officer and principal financial officer, effective July 30, 2026, under an executive employment agreement. Ahlers, age 62, brings extensive biotech finance experience, including prior roles at Intarcia Therapeutics, RenovoRx, Titan Pharmaceuticals and other life sciences companies.
The agreement provides a $450,000 annual base salary and an annual incentive bonus targeted at up to 45% of base salary. On the effective date, he received inducement equity grants under the 2026 Inducement Stock Incentive Plan: nonstatutory stock options to purchase 51,00 shares at an exercise price of $30.40 per share and a restricted stock unit award for 25,500 shares, vesting quarterly over four years. Upon certain qualifying terminations, including in connection with a change in control, he is eligible for cash severance, continued COBRA premium payments for up to nine months, and accelerated vesting of equity awards, subject to customary release and other conditions.
Cue Biopharma, Inc. granted Chief Financial Officer James M. Ahlers two equity awards on July 30, 2026: a stock option for 51,000 shares of common stock at an exercise price of $30.40 per share, expiring July 30, 2036, and 25,500 restricted stock units. Both the option and RSUs vest in equal quarterly installments over four years from July 30, 2026, subject to his continued service with the company through each vesting date.
Cue Biopharma, Inc. reports that its Chief Financial Officer, James M. Ahlers, has become a reporting insider under SEC rules through an initial statement of beneficial ownership. The filing lists no equity transactions and no reportable holdings for Ahlers at the time of this report.
Cue Biopharma Chief Executive Officer Shao-Lee Lin, through the Shao-Lee Lin Trust dated March 13, 2023, reported acquiring 90,906 pre-funded warrants and 45,453 common stock warrants on June 1, 2026. These securities were issued in a private placement under an April 30, 2026 securities purchase agreement at $11.00 per pre-funded warrant plus accompanying half-share warrant. The pre-funded warrants have a $0.001 exercise price and no expiration; the common stock warrants have an $11.00 exercise price and expire on May 4, 2031. Both series became exercisable on June 1, 2026 after stockholder approval, and the board approved the transactions under Rule 16b-3. The amendment corrects only the previously reported transaction code.
Cue Biopharma, Inc., a Delaware biotechnology company based in Boston, filed a notice of an exempt private securities offering. The company is relying on Regulation D, Rule 506(b) and has conducted a new offering of equity, warrants or other rights to acquire securities, and the securities issuable upon exercise of those rights.
The offering shows a total amount sold of $49,999,927 with $0 remaining to be sold, indicating the round is fully subscribed as reported here. The date of first sale is listed as July 13, 2026. No finders’ fees are reported, with finders’ fees stated as $0. The issuer declined to disclose its revenue range.
Cue Biopharma, Inc. granted its Chief Medical Officer and Head of Research & Development, Dominique Christian Borie, 31,500 restricted stock units (RSUs) and stock options for 63,000 shares of common stock. The options carry an exercise price of $30.9200 per share and expire on July 13, 2036.
The RSUs and options each vest in equal quarterly installments over four years starting July 13, 2026, contingent on Borie’s continued service with the company. Following these grants, Borie holds 31,500 common shares and options on 63,000 shares directly.
Cue Biopharma, Inc. reports Dominique Christian Borie, its Chief Medical Officer and Head of Research & Development, as a reporting person on a Form 3 (initial statement of beneficial ownership of securities). The Form 3 data shows no reported share transactions or derivative exercises by Borie.